

AI-Based Ocular Age Estimation from Combined OCT and OCTA Metrics: Decade-Stratified Normative Modelling in Healthy Eyes – A Pilot Study [Response to Letter]

Sayeh Pourjavan¹, Niki Nazaran², Tom Vaucourt², Nasim Abdouli³, Adil El Maftouhi⁴, Benoit Macq²

¹Department of Ophthalmology, Chirec Hospital Group, Site Delta, Brussels, Belgium; ²Institute for Information and Communication Technologies, Electronics, and Applied Mathematics (ICTEAM), Louvain School of Engineering, UCLouvain, Louvain-la-Neuve, Belgium; ³Department of Ophthalmology, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium; ⁴Centre Ophtalmologique de RIVE, Geneve, Switzerland

Correspondence: Sayeh Pourjavan, Email sayehpourjavan@gmail.com

Dear editor

We would like to sincerely thank Dr. Elsaddig for taking the time to read our article “AI-Based Ocular Age Estimation from Combined OCT and OCTA Metrics: Decade-Stratified Normative Modelling in Healthy Eyes – a Pilot Study” and for providing such thoughtful and detailed comments, especially in the context of the rapidly growing literature in this field.

We fully agree with the key points raised regarding sample size, decade-wise balance, systemic covariates, and the need for external validation and model interpretability. These are indeed genuine limitations of our current work and were deliberately and explicitly acknowledged in the manuscript, as well as reflected in the designation of this study as a pilot study.

Our primary aim was to provide a proof-of-concept normative framework that integrates structural and vascular OCT/OCTA metrics for ocular age estimation, and to do so in a transparent manner that clearly exposes its current limitations. We share entirely Dr Elsaddig’s view that:

- Larger, better-balanced, and ethnically more diverse cohorts,
- Systematic collection of systemic cardiovascular and metabolic variables,
- Independent external validation, ideally across different OCT/OCTA platforms, and
- More explicit model interpretability tools (eg SHAP or permutation-based feature importance)

These are all crucial next steps before any strong clinical claims can be made.

In fact, these elements form the core of our ongoing work. We are currently planning to extend the dataset in a multicentre setting, incorporating standardised systemic assessments and planning external validation on additional devices. We are also implementing feature-attribution approaches to better understand which structural and vascular components drive age predictions and to make the models more clinically interpretable.

We are grateful that Dr Elsaddig has highlighted these aspects so clearly. We see his letter as a constructive contribution that helps to frame our study in the appropriate context: not as a definitive statement, but as an early step towards robust, multimodal AI-based biomarkers of ocular ageing and, potentially, glaucoma susceptibility. It is precisely through such collegial critique and open discussion that the field can progress responsibly.

We thank Dr Elsaddig once again for his careful reading and valuable insights.



Disclosure

The authors report no conflicts of interest in this communication.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Ophthalmology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Ophthalmology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Ophthalmology

Dovepress
Taylor & Francis Group

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-ophthalmology-journal>

<https://doi.org/10.2147/OPTH.S579539>